Leerink Partners Trims 908 Devices (NASDAQ:MASS) Target Price to $12.00

908 Devices (NASDAQ:MASS) had its price target trimmed by Leerink Partners from $15.00 to $12.00 in a research note published on Thursday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock.

908 Devices Stock Up 4.7 %

Shares of NASDAQ MASS opened at $3.59 on Thursday. The company has a market capitalization of $123.80 million, a PE ratio of -3.36 and a beta of 0.97. 908 Devices has a twelve month low of $3.24 and a twelve month high of $12.51. The firm has a fifty day simple moving average of $3.73 and a 200 day simple moving average of $5.02.

908 Devices (NASDAQ:MASS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.02. The firm had revenue of $14.05 million during the quarter, compared to analyst estimates of $13.69 million. 908 Devices had a negative return on equity of 22.47% and a negative net margin of 72.10%. As a group, equities analysts expect that 908 Devices will post -1.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On 908 Devices

A number of institutional investors and hedge funds have recently modified their holdings of MASS. Millennium Management LLC lifted its position in shares of 908 Devices by 35.5% during the 2nd quarter. Millennium Management LLC now owns 618,310 shares of the company’s stock valued at $3,184,000 after acquiring an additional 161,922 shares during the period. ClariVest Asset Management LLC acquired a new stake in 908 Devices in the second quarter worth $668,000. Dimensional Fund Advisors LP increased its stake in 908 Devices by 88.3% in the second quarter. Dimensional Fund Advisors LP now owns 245,176 shares of the company’s stock valued at $1,263,000 after purchasing an additional 114,987 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of 908 Devices during the second quarter valued at about $585,000. Finally, Renaissance Technologies LLC boosted its position in shares of 908 Devices by 79.4% during the 2nd quarter. Renaissance Technologies LLC now owns 195,500 shares of the company’s stock worth $1,007,000 after purchasing an additional 86,500 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.